G1 therapeutics stock

G1 therapeutics stock DEFAULT

G1 Therapeutics Inc Registered Shs Stock , GTHX

G1 Therapeutics, Inc. engages in the development of small molecule therapeutics for the treatment of patients with cancer. Its products pipeline includes trilaciclib, rintodestrant, and lerociclib. The company was founded by Kwok-Kin Wong and Norman E. Sharpless on May 19, 2008 and is headquartered in Research Triangle Park, NC.

Risk

Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’s balance sheet and inputs from the stock market. The score provides a forward-looking, one-year measure of credit risk, allowing investors to make better decisions and streamline their work ow. Updated daily, it takes into account day-to-day movements in market value compared to a company’s liability structure.

Ownerin %
Freefloat79.32
SSgA Funds Management, Inc.10.35
SPDR S&P Biotech ETF8.72
Eshelman Ventures LLC8.20
MedImmune Ventures, Inc.7.03
State Street Corp.6.59
Vanguard Group, Inc. (Subfiler)5.75
Hatteras Venture Partners4.62
BlackRock Fund Advisors3.99
JPMorgan Investment Management, Inc.3.79
Wellington Management Co. LLP3.25
Wellington Management Co. LLP3.25
Dimensional Fund Advisors LP2.54
JPMorgan Small Cap Growth Fund2.52
Fidelity Management & Research Co. LLC2.43

Shareholder percentage totals can add to more than 100% because some holders are included in the free float.

Sours: https://markets.businessinsider.com/stocks/gthx-stock

G1 Therapeutics Inc

About G1 Therapeutics Inc

G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of patients with cancer. Its lead clinical compound Trilaciclib, is a therapy designed to improve outcomes for patients who are treated with chemotherapy, in clinical trials assessing myeloprotection and anti-tumor efficacy endpoints in a variety of tumors including colorectal cancer (CRC), metastatic triple negative breast cancer (mTNBC), neoadjuvant breast cancer, non-small cell lung cancer (NSCLC) and bladder cancer. Its Rintodestrant, is an oral selective estrogen receptor degrader (SERD) for the treatment of estrogen receptor-positive (ER+) breast cancer. Its Lerociclib, is a differentiated clinical-stage oral CDK4/6 inhibitor for use in combination with other targeted therapies in multiple oncology indications. Its therapies are designed to improve outcomes for patients across multiple oncology indications.

Industry

Biotechnology & Drugs

Executive Leadership

Garry A. Nicholson

Independent Chairman of the Board

John E. Bailey

President, Chief Executive Officer, Director

Jennifer K. Moses

Chief Financial Officer

Terry L. Murdock

Chief Operating Officer

Rajesh K. Malik

Chief Medical Officer, Senior Vice President - Research and Development

Key Stats

1.88 mean rating - 8 analysts

Revenue (MM, USD)
EPS (USD)

Price To Earnings (TTM)

--

Price To Sales (TTM)

8.17

Price To Book (MRQ)

2.45

Price To Cash Flow (TTM)

--

Total Debt To Equity (MRQ)

14.12

LT Debt To Equity (MRQ)

14.12

Return on Investment (TTM)

-42.62

Return on Equity (TTM)

-38.80
Sours: https://www.reuters.com/companies/GTHX.OQ
  1. Brandi williams instagram
  2. Chucks auto repair
  3. 500 watt mono amplifier

G1 TherapeuticsNasdaqGS:GTHX Stock Report

Price History & Performance

Historical stock prices
Current Share PriceUS$12.61
52 Week HighUS$10.81
52 Week LowUS$37.07
Beta2.18
1 Month Change-15.08%
3 Month Change-33.98%
1 Year Change-5.90%
3 Year Change-73.06%
5 Year Changen/a
Change since IPO-15.93%

Recent News & Updates

Sep 03
G1 Therapeutics (NASDAQ:GTHX) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

G1 Therapeutics (NASDAQ:GTHX) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...

Aug 28

G1 Therapeutics: Poised To Deliver A Blockbuster

G1 Therapeutics is now a commercialization-stage operator having a potential mega-blockbuster (Cosela). Cosela is filling a heightened demand to treat myelosuppression associated with chemotherapy. Due to the vast cancer market in dire need of better myelosuppressive drugs, Cosela is enjoying a strong industry tailwind.

Aug 16

G1 Therapeutics: Pullback Presents Opportunity

GTHX is down considerably from its February highs. Recently approved Cosela is starting out well. The company retains a lot of potential.

Aug 08
News Flash: Analysts Just Made A Captivating Upgrade To Their G1 Therapeutics, Inc. (NASDAQ:GTHX) Forecasts

News Flash: Analysts Just Made A Captivating Upgrade To Their G1 Therapeutics, Inc. (NASDAQ:GTHX) Forecasts

G1 Therapeutics, Inc. ( NASDAQ:GTHX ) shareholders will have a reason to smile today, with the analysts making...

Shareholder Returns

GTHXUS BiotechsUS Market
7D3.8%1.0%0.7%
1Y-5.9%10.6%24.8%

Return vs Industry: GTHX underperformed the US Biotechs industry which returned 8.1% over the past year.

Return vs Market: GTHX underperformed the US Market which returned 23.2% over the past year.

Price Volatility

GTHX volatility
GTHX Beta2.18
Industry Beta0.98
Market Beta1

Stable Share Price: GTHX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: GTHX's weekly volatility (7%) has been stable over the past year.

About the Company

G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase III clinical trials for patients with first line colorectal cancer, as well as Phase II clinical trials for the treatment of neoadjuvant breast cancer; lerociclib, an oral CDK4/6 inhibitor for multiple oncology indications; and rintodestrant, an oral selective estrogen receptor degrader, which is in Phase IIa clinical trials for the treatment of estrogen receptor-positive and HER2-negative breast cancer.

G1 Therapeutics Fundamentals Summary

GTHX fundamental statistics
Market CapUS$534.01m
Earnings (TTM)-US$102.88m
Revenue (TTM)US$63.97m

Earnings & Revenue

GTHX income statement (TTM)
RevenueUS$63.97m
Cost of RevenueUS$1.05m
Gross ProfitUS$62.92m
ExpensesUS$165.80m
Earnings-US$102.88m

Last Reported Earnings

Jun 30, 2021

Earnings per share (EPS)-2.43
Gross Margin98.36%
Net Profit Margin-160.84%
Debt/Equity Ratio14.1%

How did GTHX perform over the long term?

See historical performance and comparison

Valuation

Is G1 Therapeutics undervalued compared to its fair value and its price relative to the market?

2.5x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate GTHX's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate GTHX's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: GTHX is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: GTHX is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate GTHX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: GTHX is good value based on its PB Ratio (2.5x) compared to the US Biotechs industry average (2.9x).


Future Growth

How is G1 Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

17.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: GTHX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: GTHX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: GTHX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: GTHX's revenue (50.6% per year) is forecast to grow faster than the US market (9.9% per year).

High Growth Revenue: GTHX's revenue (50.6% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: GTHX is forecast to be unprofitable in 3 years.


Past Performance

How has G1 Therapeutics performed over the past 5 years?

-19.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: GTHX is currently unprofitable.

Growing Profit Margin: GTHX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: GTHX is unprofitable, and losses have increased over the past 5 years at a rate of 19.8% per year.

Accelerating Growth: Unable to compare GTHX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: GTHX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).


Return on Equity

High ROE: GTHX has a negative Return on Equity (-48.26%), as it is currently unprofitable.


Financial Health

How is G1 Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: GTHX's short term assets ($265.7M) exceed its short term liabilities ($25.6M).

Long Term Liabilities: GTHX's short term assets ($265.7M) exceed its long term liabilities ($37.9M).


Debt to Equity History and Analysis

Debt Level: GTHX's debt to equity ratio (14.1%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if GTHX's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: GTHX has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: GTHX has sufficient cash runway for 1.4 years if free cash flow continues to reduce at historical rates of 23.5% each year.


Dividend

What is G1 Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate GTHX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate GTHX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if GTHX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if GTHX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of GTHX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.8yrs

Average management tenure


CEO

Mr. John E. Bailey, also known as Jack, Jr. has been Director at G1 Therapeutics, Inc. since March 2020. He serves as President and Chief Executive Officer at G1 Therapeutics Inc. since January 1, 2021. Mr...


Leadership Team

Experienced Management: GTHX's management team is considered experienced (2.8 years average tenure).


Board Members

Experienced Board: GTHX's board of directors are considered experienced (4.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 11.4%.


Top Shareholders

Company Information

G1 Therapeutics, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: G1 Therapeutics, Inc.
  • Ticker: GTHX
  • Exchange: NasdaqGS
  • Founded: 2008
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$534.013m
  • Shares outstanding: 42.35m
  • Website: https://www.g1therapeutics.com

Number of Employees


Location

  • G1 Therapeutics, Inc.
  • 700 Park Offices Drive
  • Suite 200
  • Research Triangle Park
  • North Carolina
  • 27709
  • United States

Listings


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2021/10/13 22:42
End of Day Share Price2021/10/13 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Sours: https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-gthx/g1-therapeutics
  • Price (USD)12.62
  • Today's Change0.01 / 0.08%
  • Shares traded225.74k
  • 1 Year change-5.82%
  • Beta2.1776

Data delayed at least 15 minutes, as of Oct 14 2021 20:44 BST.

More ▼

Take Action

Take Action

Add this security to watchlist, portfolio, or create an alert to track market movement

Add to Your Watchlists

Add to Your Portfolio

You must be a registered user to save alerts. Please sign in or register.

  • GTHX:NSQ price moved over -1.15% to 12.00

As of last trade, traded at 12.62, 16.74% above the 52 week low of 10.81 set on Oct 30, 2020.

Today

10.81Oct 30 202037.07Feb 16 2021

Open12.72
High12.91
Low12.58
Bid12.62
Offer12.63
Previous close12.61

Data delayed at least 15 minutes, as of Oct 14 2021 20:44 BST.

More ▼

Refinitiv
An LSEG Business

All markets data located on FT.com is subject to the FT Terms & Conditions

All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.

Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.

Markit Short Selling Activity © Markit. All rights reserved.

Although Markit has made every effort to ensure this data is correct, nevertheless no guarantee is given to the accuracy or completeness. Any opinions or estimates expressed herein are those of Markit on the date of preparation and are subject to change without notice; however no such opinions or estimates constitute legal, investment or other advice. You must therefore seek independent legal, investment or other appropriate advice from a suitably qualified and/or authorised and regulated advisor prior to making any legal, investment or other decision. This is intended for information purposes only and is not intended as an offer or recommendation to buy, sell or otherwise deal in securities.

imageSours: https://markets.ft.com/data/equities/tearsheet/summary?s=GTHX:NSQ

Stock g1 therapeutics

Invest in G1 Therapeutics Inc on Stash

Historical performance data are provided “as is” and solely for information purposes, is not advice or for trading purposes, does not reflect an investment strategy, may be subject to pricing delays, should not be used for tax reporting, may not reflect actual performance, and are gross of Stash fees. Market data provided by Thomson Reuters (Refinitiv). ©2021 Thomson Reuters. Stash cannot and does not represent or guarantee that any of the information available via Refinitiv is accurate, reliable, current, complete or appropriate for your needs. This material does not contain sufficient information to support an investment decision and it should not be relied upon by you in evaluating the merits of investing in any securities or products. In addition, users should make an independent assessment of the legal, regulatory, tax, credit and accounting implications and determine performance and yield are not a reliable indicator of current and future results.

Sours: https://www.stash.com/investments/stocks/g1-therapeutics-inc-gthx/
Акции G1 Therapeutics, Inc. (GTHX) Куда идет ПЕРЧ?

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock quotes are delayed as per exchange requirements. Fundamental company data and analyst estimates provided by FactSet. Copyright 2019© FactSet Research Systems Inc. All rights reserved. Source: FactSet

Indexes: Index quotes may be real-time or delayed as per exchange requirements; refer to time stamps for information on any delays. Source: FactSet

Markets Diary: Data on U.S. Overview page represent trading in all U.S. markets and updates until 8 p.m. See Closing Diaries table for 4 p.m. closing data. Sources: FactSet, Dow Jones

Stock Movers: Gainers, decliners and most actives market activity tables are a combination of NYSE, Nasdaq, NYSE American and NYSE Arca listings. Sources: FactSet, Dow Jones

ETF Movers: Includes ETFs & ETNs with volume of at least 50,000. Sources: FactSet, Dow Jones

Bonds: Bond quotes are updated in real-time. Sources: FactSet, Tullett Prebon

Currencies: Currency quotes are updated in real-time. Sources: FactSet, Tullett Prebon

Commodities & Futures: Futures prices are delayed at least 10 minutes as per exchange requirements. Change value during the period between open outcry settle and the commencement of the next day's trading is calculated as the difference between the last trade and the prior day's settle. Change value during other periods is calculated as the difference between the last trade and the most recent settle. Source: FactSet

Data are provided 'as is' for informational purposes only and are not intended for trading purposes. FactSet (a) does not make any express or implied warranties of any kind regarding the data, including, without limitation, any warranty of merchantability or fitness for a particular purpose or use; and (b) shall not be liable for any errors, incompleteness, interruption or delay, action taken in reliance on any data, or for any damages resulting therefrom. Data may be intentionally delayed pursuant to supplier requirements.

Mutual Funds & ETFs: All of the mutual fund and ETF information contained in this display, with the exception of the current price and price history, was supplied by Lipper, A Refinitiv Company, subject to the following: Copyright 2019© Refinitiv. All rights reserved. Any copying, republication or redistribution of Lipper content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Lipper. Lipper shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Cryptocurrencies: Cryptocurrency quotes are updated in real-time. Sources: CoinDesk (Bitcoin), Kraken (all other cryptocurrencies)

Calendars and Economy: 'Actual' numbers are added to the table after economic reports are released. Source: Kantar Media

Sours: https://www.wsj.com/market-data/quotes/GTHX

Similar news:

G1 Therapeutics Inc (NASDAQ:GTHX)

Most stock quote data provided by BATS. Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer. Morningstar: © 2019 Morningstar, Inc. All Rights Reserved. Factset: FactSet Research Systems Inc.2019. All rights reserved. Chicago Mercantile Association: Certain market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. Dow Jones: The Dow Jones branded indices are proprietary to and are calculated, distributed and marketed by DJI Opco, a subsidiary of S&P Dow Jones Indices LLC and have been licensed for use to S&P Opco, LLC and CNN. Standard & Poor's and S&P are registered trademarks of Standard & Poor's Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. All content of the Dow Jones branded indices © S&P Dow Jones Indices LLC 2019 and/or its affiliates.

© 2021 Cable News Network. A Warner Media Company. All Rights Reserved.
CNN Sans™ & © 2016 Cable News Network.

Sours: https://money.cnn.com/quote/forecast/forecast.html?symb=GTHX


84 85 86 87 88